TBA Co.,Ltd.

TBA Co.,Ltd. | R&D and manufacturing for rapid genetic tests

JAPANESE

News Release

NIKKEI article on our project in Vietnam

 Press announcement, Topics

Our project with Vietnamese partner was published on an article of NIKKEI Newspaper (Tohoku local section) dated 30March2019.

Here is link of the article copy and its translation into English.

Thank you.

 

Article copy

/en_article/f/20190409112335527512.pdf

English translation

/en_article/f/20190409112356903331.pdf

 

BioJapan 2018

 Press announcement, Topics

We exhibited at BioJapan 2018, held in Yokohama during 10th - 12th October. Thank you all for coming to our booth and matching-meetings. 

BioJapan2018_2

Japan-Mekong Business Forum

 Press announcement, Topics

Mekong-Japan Summit was held in Tokyo recently. On this occasion, Japan-Mekong Business Forum was held in Palace Hotel Tokyo on 9th October 2018, with the heads of five Mekong countries invited, hosted by JETRO (Japan External Trade Organization) and AMEICC (AEM-METI Economic and Industrial Cooperation Commitee). 

During the program, as part of the session "Presentation: Demonstration Project by JETRO", our President & Representative Director Dr. Mitsuo Kawase spoke about our on-going project in Vietnam "Production and sales demonstration of STH-PAS, genetic testing kit in Vietnam".

 

2251

President change

 Company history

We are pleased to announce that Mitsuo Kawase has been appointed as new Representative Director and President, as of September 1, 2018, and that Tadahiko Inukai remains as Representative Director and Chairman.

Thank you for your continued support.

Medical Fair Asia 2018

 Press announcement, Topics

We exhibited at Medical Fair Asia 2018 in Singapore during 29th - 31st August 2018. We had meetings with current partners and new visitors. We also presented update for our product at the business stage.

Thank you all for coming to our exhibition!

Business Stage 1_resized

 

booth 3_resized

 

HHM Global Magazine

 Press announcement, Topics

The article featuring our compnay and product has been published by the Hospital & Healthcare Management Global Magazine, as one of innovative products showcased at upcoming Medical Fair Asia 2018 in Singapore. Attached please find the copy for your reference. Thank you.

/en_article/f/20181026094451624323.pdf

Healthcare Asia Daily News

 Press announcement, Topics

The article featuring our compnay and product has been picked up by Healthcare Asia Daily News (online), as one of innovative diagnostic products showcased at upcoming Medical Fair Asia 2018 in Singapore. Below is the link for your reference. Thank you.

http://www.healthcareasia.org/2018/quicker-accurate-diagnoses-for-dangerous-diseases-and-genetic-disorders/

Special feature: CRE

 Special feature

Do you know carbapenem-resistant Enterobacteriaceae bacteria?

 

Carbapenem is a kind of antibiotics, which are widely used for many kinds of bacterial infection. It is called as an “antibiotics of last resort “because it is effective for multidrug-resistant bacteria.

On the other hand, due to its versatility, excessive use is thought to be the cause of the spread of carbapenem-resistant Enterobacteriaceae bacteria (CRE). As only a few antibiotics against CRE infection are available, it is important to confirm the presence of CRE at an early stage in order to prevent the spread of CRE.

 

In order to confirm the presence of CRE, genetic testing is necessary because just identifying bacterial species is not effective since various kinds of bacteria acquire resistance. Therefore, detection of genes which involve in the production of carbapenemase, which is an enzyme that degrades carbapenem is needed.  

However, genetic testing cannot be conducted easily.

 

カルバペネム 写真1

                       Image photo

 

In this situation, a professor from Osaka University, Japan, developed an epoch-making genetic testing method to easily inspect carbapenem-resistant bacteria on site. This method can detect major type of carbapenemase genes. The carbapenemase genes from samples such as patient's stool are amplified by PCR, and then the result can be visually recognized by the genetic testing strip C-PAS. If a blue line appears on C-PAS, it tells existence of bacteria which is tolerant to carbapenem, unfortunately.


カルバペネム 写真2

                                      Detection process at the professor’s laboratory

 

In this method, inspection results can be obtained in about 2 hours from sample collection. As an example of actual experimental results, compared with electrophoresis, Sensitivity was 93.3%, Specificity was 99.1%.It means the carbapenemase gene could be detected with high accuracy.

The professor says, “with this method, it is possible to carry out inspection with high accuracy easily even in places where expensive equipment and facilities are not installed and prevention method against the spread of CRE might be greatly advanced.” 

 

カルバペネム 写真3

                       Genetic testing strip “C-PAS”

 

TBA is pleased to be involved in a major advance in realization of onsite inspection.

Scientific paper: Antimicrobial Agents and Chemotherapy, June 2017, Vol61, Issue6, e00067-17

 

 

 

TBA co,.ltd.

Wanted: Business partner!

 Special feature

Wanted: Business partner!
Company that can manufacture and sell diagnosis kit

 

We sell genetic testing strip C-PAS which can easily detect the target gene. It is also used as a diagnostic tool for infectious diseases.
Since we are a company supplying this C-PAS as a raw material of the kit, we are looking for kit manufacturers to process into final products and sell them to final users.

 

Requirements as kit manufacturers are:
1) Manufacturing facility for diagnostic kit
  (Development of final kit, enough for dispensing of liquid reagent,)
2) Sales to customers such as hospitals under your own brand name
3) Acquisition of Pharmaceutical approval (if needed)

Spply Chain _170602

Please cooperate with us if you are a company that can do business like this.

We are confident in the technology and quality of the STH-PAS method. The advantage of this method is that 1) convenience that no expensive equipment is necessary and can be used by anyone, 2) high sensitivity thanks to hybrid between tags, 3) Multiplex that can detect up to 12 different genes at once.

 

Take advantage of this strength and do the work of delivering the testing kit to those who need a quicker and more accurate diagnosis.

医者と看護し

The technology called nucleic acid chromatography is still rare in the world.
Why was there no nucleic acid chromatography so far? Because genetic testing is thought to be done in well-equipped places, it was not necessary to make it easy.

However, imagining where infectious diseases are prevalent, a quick test result is needed. And diagnosis of infectious diseases has to be possible even in places without well facilities and few experts. Such demand is quite high.

 

Currently, a certain diagnostic drug manufacturer in China become a business partner and is preparing for sale of kit for such as sexually transmitted disease, M. tuberculosis and respiratory infectious disease. Although there are few partners so far, it means it is a good opportunity to expand nucleic acid chromatography on the market.

 

If you are interested in or have any question, please contact us through our homepage.

 

TBA co,.ltd.

Medical Fair Thailand 2017

 Press announcement, Topics

TBA has exhibited our products at Medical Fair Thailand 2017 at Bangkok on Sep 6-8,2017.

In addition, our sales manager gave a presentation at 11:30~12:00 on the Sep 7th at Forum Stage.

It was our pleasure that many people visited our booth.

DSC_45061504783650930

 

 

 

MFT2017